@article{3e271cb803034347ab31c2748801aa30,
title = "17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson{\textquoteright}s disease are associated with LRRC37A/2 expression in astrocytes",
abstract = "Background: Parkinson{\textquoteright}s disease (PD) is genetically associated with the H1 haplotype of the MAPT 17q.21.31 locus, although the causal gene and variants underlying this association have not been identified. Methods: To better understand the genetic contribution of this region to PD and to identify novel mechanisms conferring risk for the disease, we fine-mapped the 17q21.31 locus by constructing discrete haplotype blocks from genetic data. We used digital PCR to assess copy number variation associated with PD-associated blocks, and used human brain postmortem RNA-seq data to identify candidate genes that were then further investigated using in vitro models and human brain tissue. Results: We identified three novel H1 sub-haplotype blocks across the 17q21.31 locus associated with PD risk. Protective sub-haplotypes were associated with increased LRRC37A/2 copy number and expression in human brain tissue. We found that LRRC37A/2 is a membrane-associated protein that plays a role in cellular migration, chemotaxis and astroglial inflammation. In human substantia nigra, LRRC37A/2 was primarily expressed in astrocytes, interacted directly with soluble α-synuclein, and co-localized with Lewy bodies in PD brain tissue. Conclusion: These data indicate that a novel candidate gene, LRRC37A/2, contributes to the association between the 17q21.31 locus and PD via its interaction with α-synuclein and its effects on astrocytic function and inflammatory response. These data are the first to associate the genetic association at the 17q21.31 locus with PD pathology, and highlight the importance of variation at the 17q21.31 locus in the regulation of multiple genes other than MAPT and KANSL1, as well as its relevance to non-neuronal cell types.",
keywords = "17q21.31, Astrocytes, Copy number variation, LRRC37A, Parkinson{\textquoteright}s disease",
author = "{International Parkinson's Disease Genomics Consortium (IPDGC)} and Bowles, {Kathryn R.} and Pugh, {Derian A.} and Yiyuan Liu and Tulsi Patel and Renton, {Alan E.} and Sara Bandres-Ciga and Ziv Gan-Or and Peter Heutink and Ari Siitonen and Sarah Bertelsen and Cherry, {Jonathan D.} and Karch, {Celeste M.} and Frucht, {Steven J.} and Kopell, {Brian H.} and Inga Peter and Park, {Y. J.} and Alexander Charney and Towfique Raj and Crary, {John F.} and Goate, {A. M.}",
note = "Funding Information: We thank the Icahn School of Medicine at Mount Sinai Neuropathology Brain Bank CoRE for supplying post-mortem human brain tissues for analysis. We are grateful to the brank bank participants and their families for their contributions to research. Data used in the preparation of this article were obtained from the Accelerating Medicine Partnership{\textregistered} (AMP{\textregistered}) Parkinson{\textquoteright}s Disease (AMP PD) Knowledge Platform. For up-to-date information on the study, visit https://www.amp-pd.org. The AMP{\textregistered} PD program is a public-private partnership managed by the Foundation for the National Institutes of Health and funded by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Aligning Science Across Parkinson's (ASAP) initiative; Celgene Corporation, a subsidiary of Bristol-Myers Squibb Company; GlaxoSmithKline plc (GSK); The Michael J. Fox Foundation for Parkinson's Research ; Pfizer Inc.; Sanofi US Services Inc.; and Verily Life Sciences. ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services. Genome sequence data for the Lewy body dementia case-control cohort were generated at the Intramural Research Program of the U.S. National Institutes of Health. The study was supported in part by the National Institute on Aging (program #: 1ZIAAG000935) and the National Institute of Neurological Disorders and Stroke (program #: 1ZIANS003154). PPMI is sponsored by The Michael J. Fox Foundation for Parkinson{\textquoteright}s Research and supported by a consortium of scientific partners: [list the full names of all of the PPMI funding partners found at https://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors]. The PPMI investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org. We are grateful to the New York Stem Cell Foundation for contributing iPSC lines for this study, as well as the New South Wales Brain Bank. Peripheral blood monon uclear cells (PBMCs) were obtained from the New South Wales Brain Bank at Neuroscience Research Australia, which is supported by the University of New South Wales and Neuroscience Research Australia. We thank the Icahn School of Medicine at Mount Sinai core for iPSC reprogramming services. Funding Information: This work was supported by funding from the BrightFocus Foundation (KRB), Association for Frontotemporal Degeneration (KRB) and CurePSP (KRB). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. NIH AG062683 (J.TCW), Rainwater Charitable Organization (CMK), NIH AG046374 (CMK). The McGill cohort was supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program, and Parkinson Canada. ZGO is supported by the Fonds de recherche du Qu{\'e}bec—Sant{\'e} (FRQS) Chercheurs-boursiers award given with Parkinson Quebec, and is a Parkinson Canada New Investigator awardee. The access to the McGill participants for this research has been made possible in part thanks to the Quebec Parkinson{\textquoteright}s Network ( http://rpq-qpn.ca/en/ ). NIH [R01AG054008, R01NS095252, R01AG060961, R01 AG060961] to JFC, the Rainwater Charitable Foundation/Tau Consortium (JFC), Genentech/Roche, and an Alexander Saint-Amand Scholarship (JFC). This work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services: project numbers 1ZIA-NS003154, Z01-AG000949-02 and Z01-ES101986. BrightFocus Foundation,Association for Frontotemporal Degeneration,CurePSP,Rainwater Charitable Foundation,National Institutes of Health,Michael J. Fox Foundation for Parkinson's Research,Canadian Consortium on Neurodegeneration in Aging,Canada First Research Excellence Fund,Fonds de Recherche du Qu{\'e}bec—Sant{\'e} Funding Information: We thank the Icahn School of Medicine at Mount Sinai Neuropathology Brain Bank CoRE for supplying post-mortem human brain tissues for analysis. We are grateful to the brank bank participants and their families for their contributions to research. Data used in the preparation of this article were obtained from the Accelerating Medicine Partnership{\textregistered} (AMP{\textregistered}) Parkinson{\textquoteright}s Disease (AMP PD) Knowledge Platform. For up-to-date information on the study, visit https://www.amp-pd.org . The AMP{\textregistered} PD program is a public-private partnership managed by the Foundation for the National Institutes of Health and funded by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Aligning Science Across Parkinson's (ASAP) initiative; Celgene Corporation, a subsidiary of Bristol-Myers Squibb Company; GlaxoSmithKline plc (GSK); The Michael J. Fox Foundation for Parkinson's Research ; Pfizer Inc.; Sanofi US Services Inc.; and Verily Life Sciences. ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services. Genome sequence data for the Lewy body dementia case-control cohort were generated at the Intramural Research Program of the U.S. National Institutes of Health. The study was supported in part by the National Institute on Aging (program #: 1ZIAAG000935) and the National Institute of Neurological Disorders and Stroke (program #: 1ZIANS003154). PPMI is sponsored by The Michael J. Fox Foundation for Parkinson{\textquoteright}s Research and supported by a consortium of scientific partners: [list the full names of all of the PPMI funding partners found at https://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors ]. The PPMI investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org . We are grateful to the New York Stem Cell Foundation for contributing iPSC lines for this study, as well as the New South Wales Brain Bank. Peripheral blood monon uclear cells (PBMCs) were obtained from the New South Wales Brain Bank at Neuroscience Research Australia, which is supported by the University of New South Wales and Neuroscience Research Australia. We thank the Icahn School of Medicine at Mount Sinai core for iPSC reprogramming services. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1186/s13024-022-00551-x",
language = "English",
volume = "17",
journal = "Molecular neurodegeneration",
issn = "1750-1326",
number = "1",
}